Eli Lilly and Co
(LSE:LEL)
$
56.25
0 (1.24%)
Market Cap: 63.81 Bil
Enterprise Value: 91.49 Bil
PE Ratio: 87.15
PB Ratio: 50.94
GF Score: 87/100 
Eli Lilly and Co at Bank of America Healthcare Conference Transcript
May 10, 2022 / 11:40PM GMT
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
Perfect. Well, welcome to the final session of the day in the grand ballroom. It's a big room, but very big shoes to fill. So we have Dan Skovronsky, who is CSO and Chief Medical Officer of Eli Lilly. Dan, thanks a lot for coming.
Daniel M. Skovronsky
Eli Lilly and Company - Senior VP, Chief Scientific & Medical Officer and President of Lilly Research Labs
Thanks for having us, Geoff.
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
So it's interesting, with a lot of companies that I have done Q&As with, there is sometimes a little bit of a shortage of good content. But for you guys, though, there's lots of something to talk about.
Daniel M. Skovronsky
Eli Lilly and Company - Senior VP, Chief Scientific & Medical Officer and President of Lilly Research Labs
It's a busy time in R&D at Lilly, but super exciting times.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers